Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 16/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.44 |
| ▸ | IL1B | P01584 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19256197 | 1.00 | HCRTR1 (0.45) | HCRTR1HCRTR2IL1B | |
| SCHEMBL19256198 | 1.00 | HCRTR1 (0.45) | HCRTR1HCRTR2IL1B | |
| SCHEMBL24381177 | 1.00 | HCRTR1 (0.45) | HCRTR1HCRTR2IL1B | |
| Bromide SCHEMBL19207102 | 0.99 | HCRTR1 (0.45) | HCRTR1HCRTR2IL1B | |
| Bromide SCHEMBL29560199 | 0.99 | HCRTR1 (0.45) | HCRTR1HCRTR2IL1B | |
| SCHEMBL19256528 | 0.86 | HCRTR1 (0.44) | HCRTR1 | |
| SCHEMBL19256523 | 0.86 | HCRTR1 (0.44) | HCRTR1 | |
| SCHEMBL19256527 | 0.86 | HCRTR1 (0.44) | HCRTR1 | |
| Bromide SCHEMBL19207100 | 0.85 | HCRTR1 (0.44) | HCRTR1 | |
| SCHEMBL19256193 | 0.82 | HCRTR1 (0.44) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3414241-B1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2022-05-04 | — | — | EP | disclosed |
| US-20210214348-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | NIUVERA BIO, INC. | 2021-07-15 | — | — | US | disclosed |
| US-10894789-B2 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB (SE) | 2021-01-19 | — | — | US | disclosed |
| US-20190135800-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | EOLAS THERAPEUTICS, INC. | 2019-05-09 | — | — | US | disclosed |
| WO-2017139603-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2017-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894789-B2 | Halo-substituted piperidines as orexin receptor modulators | HCRTR2, HCRTR1, OPRD1 | HCRTR1 2/4885HCRTR2 1/4885IL1B 3583/4885 |
| US-20190135800-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OPRD1 | HCRTR1 2/4885HCRTR2 1/4885IL1B 3583/4885 |
| US-20210214348-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OPRD1 | HCRTR1 2/4885HCRTR2 1/4885IL1B 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.